Rubitecan

Rubitecan (Orathecin): An Insight into Topoisomerase Inhibitors[edit]

Rubitecan (International Nonproprietary Name - INN) commercialized as Orathecin, is a potent oral topoisomerase inhibitor hailing from the family of anticancer agents. Initially developed by SuperGen, this compound now lies under the stewardship of Astex Pharmaceuticals, Inc., a subsidiary of the renowned Otsuka Group.

Synthesis[edit]

The synthesis of Rubitecan, especially on a large scale, has presented significant challenges, with certain steps proving problematic.

Regioselectivity Issues: The direct nitration of camptothecin, a precursor in Rubitecan's synthesis, doesn't always yield the desired product due to regioselectivity issues^[1].
Alternative Approach: One workaround to the above challenge is to initially nitrate 10-hydroxycamptothecin and then proceed to eliminate the hydroxyl functional group, giving rise to Rubitecan^[2].

Use as an Anti-Cancer Drug[edit]

Rubitecan's anticancer activity, particularly its potential against pancreatic cancer and various solid tumors, has made it a significant subject of oncology research.

Mechanism of Action: As a topoisomerase inhibitor, Rubitecan works by interfering with the action of topoisomerase enzymes, thus preventing the unwinding of DNA required for replication and transcription. This effectively halts tumor growth^[3].
Bioavailability Concerns: Despite its potency, Rubitecan’s utility is hampered by its poor oral bioavailability. This is attributed to its low permeability coupled with dismal water solubility^[4].
Novel Delivery Method: Research indicates that using a Soluplus1-based solid dispersion system (9-NC-SD) to deliver Rubitecan might circumvent the bioavailability issues, presenting a more effective delivery mechanism as compared to the conventional 9-NC^[5].

Conclusion[edit]

Rubitecan's journey from synthesis to its potential therapeutic applications in oncology underscores both the challenges and innovations in the realm of drug discovery and development. While obstacles remain, evolving research, particularly in drug delivery, offers hope for maximizing the utility of this promising anticancer agent.

References[edit]

↑ Shao, Y. et al. (2007). Modified synthesis of 9-nitrocamptothecin. Journal of Chemical Research.
↑ Kim, D. H., et al. (2013). Synthetic approaches to the 2008 new drugs. Bioorganic & Medicinal Chemistry, 21(16), 5005-5102.
↑ Pommier, Y. (2006). Topoisomerase I inhibitors: camptothecins and beyond. Nature Reviews Cancer, 6(10), 789-802.
↑ Luo, C., et al. (2011). Amorphous solid dispersion of 9-nitrocamptothecin with improved oral bioavailability. International journal of pharmaceutics, 413(1-2), 167-173.
↑ Li, S., et al. (2014). Soluplus®/TPGS-based solid dispersions prepared by hot-melt extrusion equipped with twin-screw systems for enhancing oral bioavailability of valsartan. Acta Pharmaceutica Sinica B, 4(5), 333-341.

This WikiMD article can only be edited by registered and verified editors. You can log in or register.

Navigation-> Medicine - Wellness - Encyclopedia - Health topics - Diseases - Drugs - Gray's Anatomy - W8MD diet - Ketogenic diet - Recipes

Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Translate page: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian

[1] Shao, Y. et al. (2007). Modified synthesis of 9-nitrocamptothecin. Journal of Chemical Research.

[2] Kim, D. H., et al. (2013). Synthetic approaches to the 2008 new drugs. Bioorganic & Medicinal Chemistry, 21(16), 5005-5102.

[3] Pommier, Y. (2006). Topoisomerase I inhibitors: camptothecins and beyond. Nature Reviews Cancer, 6(10), 789-802.

[4] Luo, C., et al. (2011). Amorphous solid dispersion of 9-nitrocamptothecin with improved oral bioavailability. International journal of pharmaceutics, 413(1-2), 167-173.

[5] Li, S., et al. (2014). Soluplus®/TPGS-based solid dispersions prepared by hot-melt extrusion equipped with twin-screw systems for enhancing oral bioavailability of valsartan. Acta Pharmaceutica Sinica B, 4(5), 333-341.

[1]

[2]

[3]

[4]

[5]